Allogene Therapeutics (ALLO) Payables (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Payables data on file, last reported at $4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 2.47% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at $4.9 million (down 2.47% YoY), and the FY2025 full-year result was $4.3 million, down 20.84% from the prior year.
• Payables climbed to $4.9 million in Q1 2026, from $4.3 million in the prior quarter.
• In the past five years, Payables ranged from a high of $14.7 million in Q1 2023 to a low of $3.7 million in Q3 2025.
• A 5-year average of $7.8 million and a median of $5.9 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables surged 68.67% in 2023 and slumped 62.5% in 2025, its largest moves.
• Tracing ALLO's Payables over 5 years: stood at $13.9 million in 2022, then plunged by 57.54% to $5.9 million in 2023, then decreased by 8.53% to $5.4 million in 2024, then retreated by 20.84% to $4.3 million in 2025, then gained by 15.53% to $4.9 million in 2026.
• Business Quant data shows ALLO's Payables at $4.9 million in Q1 2026, $4.3 million in Q4 2025, and $3.7 million in Q3 2025.